Related Experiment Video

Updated: May 13, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Trial watch: Monoclonal antibodies in cancer therapy

Erika Vacchelli1, Alexander Eggermont, Jérôme Galon

  • 1Institut Gustave Roussy; Villejuif, France ; Université Paris-Sud/Paris XI; Le Kremlin-Bicêtre, France ; INSERM; U848; Villejuif, France.

Oncoimmunology
|March 14, 2013
PubMed

Insights

Monoclonal antibodies are revolutionizing cancer treatment by enhancing immune responses, blocking cancer cell signaling, and delivering toxins. Recent advancements and clinical trials highlight their growing efficacy in treating various malignancies.

Area of Science:

  • Oncoimmunology
  • Cancer Therapy
  • Antibody Engineering

Background:

  • Over the past two decades, significant progress has been made in developing monoclonal antibodies for cancer treatment.
  • These antibodies target cancer through various mechanisms, including immune response modulation, signal transduction inhibition, targeted toxin delivery, and disruption of tumor-stroma interactions.
  • The U.S. Food and Drug Administration (FDA) has approved 14 monoclonal antibodies for treating hematological and solid tumors.

Purpose of the Study:

  • To summarize recent high-impact studies on monoclonal antibodies in cancer therapy published within the last 15 months.
  • To review newly launched clinical trials investigating novel monoclonal antibodies for cancer treatment.
  • To provide an update on the latest developments in the field of oncoimmunology.

Main Methods:

  • Literature review of high-impact studies published in the last 15 months.
  • Analysis of clinical trials initiated during the same period.
  • Focus on studies investigating the safety and efficacy of monoclonal antibodies in cancer patients.

Main Results:

  • The field has seen substantial research leading to FDA-approved monoclonal antibodies for various cancers.
  • Ongoing research continues to explore new therapeutic strategies and targets for monoclonal antibody development.
  • Numerous clinical trials are underway to evaluate the potential of investigational monoclonal antibodies.

Conclusions:

  • Monoclonal antibodies represent a significant and evolving therapeutic modality in oncology.
  • Continued research and clinical investigation are crucial for advancing cancer treatment with monoclonal antibodies.
  • The latest developments indicate a promising future for antibody-based cancer therapies.
Keywords:
bevacizumabdalotuzumabipilimumabnimotuzumabramucirumabtrastuzumab

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...